Open AccessEffect of Amphotericin B and Rifampin Against Coccidioides immitis In Vitro and In Vivo
Author(s) -
M. Huppert,
Demosthenes Pappagianis,
Steven Sun,
I. Gleason-Jordan,
Michael Collins,
Katherine Vukovich
Publication year - 1976
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.9.3.406
Subject(s) - amphotericin b , coccidioides immitis , coccidioides , antibiotics , microbiology and biotechnology , in vivo , pharmacology , drug , biology , medicine , antifungal
Amphotericin B, the principal drug used for treating systemic mycoses, possesses undesirable toxic properties. The ability of this antibiotic to potentiate antifungal activity of other compounds suggests that lower doses of amphotericin B could be used in combination with a second drug without loss of therapeutic efficacy. In vitro tests demonstrated that amphotericin B potentiated rifampin against the mycelial growth phase ofCoccidioides immitis but not against the spherule-endospore phase. Therapy for murine coccidioidomycosis with a combined amphotericin B-rifampin regimen was not better than treatment with amphotericin B alone; in fact, combined drugs may have been even less effective. This would have clinical significance for therapy of concurrent infections.